RP1 Plus Nivolumab Represents the Next Frontier of Oncolytic Virus–Based Therapy for Melanoma
Source: OncLive, May 2025
Anna C. Pavlick, BSN, MSc, DO, MBA, discusses data for RP1 plus nivolumab and the evolving treatment landscape in advanced melanoma.
RP1 combined with nivolumab (Opdivo) has yielded durable responses in patients with advanced melanoma after prior immune checkpoint inhibition, offering a promising therapeutic option for those with limited treatment alternatives, according to Anna C. Pavlick, BSN, MSc, DO, MBA.
The phase 1/2 IGNYTE trial (NCT03767348) is investigating RP1 in combination with nivolumab in patients with cutaneous melanoma who have progressed on prior anti–PD-1 therapy. Data presented at the 2024 SITC Annual Meeting showed that among 140 evaluable patients, the overall response rate (ORR) per modified RECIST 1.1 criteria was 33.6%, including respective complete response (CR) and partial response (PR) rates of 15.0% and 18.6%.1 Furthermore, the 12-month duration of response (DOR) rate was 70.5%, and the median DOR was 21.6 months (range, 1.2+ to 43.5+).